Production (Stage)
Evofem Biosciences, Inc.
EVFM
$0.01
$0.00044.17%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 845.00K | 7.10M | 4.50M | 4.16M | 3.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 845.00K | 7.10M | 4.50M | 4.16M | 3.60M |
| Cost of Revenue | 365.00K | 1.51M | 869.00K | 769.00K | 684.00K |
| Gross Profit | 480.00K | 5.59M | 3.63M | 3.39M | 2.92M |
| SG&A Expenses | 4.97M | 11.26M | 5.43M | 4.51M | 5.17M |
| Depreciation & Amortization | 223.00K | 318.00K | 301.00K | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 518.00K | 8.11M | 6.94M | 5.55M | 6.45M |
| Operating Income | 327.00K | -1.00M | -2.44M | -1.39M | -2.84M |
| Income Before Tax | 956.00K | -3.04M | -2.37M | 1.36M | -4.81M |
| Income Tax Expenses | -- | -- | -8.00K | 8.00K | -- |
| Earnings from Continuing Operations | 956.00K | -3.04M | -2.37M | 1.35M | -4.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 956.00K | -3.04M | -2.37M | 1.35M | -4.81M |
| EBIT | 327.00K | -1.00M | -2.44M | -1.39M | -2.84M |
| EBITDA | 556.00K | -680.00K | -2.13M | -1.38M | -2.83M |
| EPS Basic | 0.01 | -0.03 | -0.02 | 0.02 | -0.16 |
| Normalized Basic EPS | 0.01 | -0.02 | -0.01 | 0.01 | -0.12 |
| EPS Diluted | 0.00 | -0.03 | -0.02 | 0.00 | -0.16 |
| Normalized Diluted EPS | 0.00 | -0.02 | -0.01 | 0.00 | -0.12 |
| Average Basic Shares Outstanding | 113.36M | 105.79M | 96.46M | 66.77M | 31.19M |
| Average Diluted Shares Outstanding | 6.04B | 105.79M | 96.46M | 1.61B | 31.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |